NCT06932757View on ClinicalTrials.gov

Adjuvant Quisinostat in High-Risk Uveal Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

May 27, 2030

Study Completion Date

May 27, 2030

Conditions
Uveal Melanoma
Interventions
DRUG

Quisinostat

Participants will receive 12 mg of Quisinostat via capsule to be taken orally three times per week of each 21 day cycle.

Trial Locations (1)

33136

RECRUITING

University of Miami, Miami

Sponsors

Collaborators (1)

Viriom
All Listed Sponsors
collaborator

Viriom

INDUSTRY

collaborator

Joseph and Florence Mandel Family Foundation

UNKNOWN

lead

University of Miami

OTHER